Parkinsn's Email List Message

Posting to the Parkinsn List is a benefit of Subscription


[Message Prev][Message Next][Thread Prev][Thread Next][Message Index][Thread Index]

PMID: 9537825: Entacapone does not impair mitochondrial energy production.


Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's
disease, does not impair mitochondrial energy production.

Entacapone, a novel mainly peripherally acting catechol-O-methyltransferase 
inhibitor used in the treatment of Parkinson's disease, was evaluated for its 
possible uncoupling activity in cell culture, in rat liver mitochondria, and in 
isolated guinea-pig heart.

Entacapone did not stimulate respiration in the L1210 murine T cell lymphoma 
cell line at the concentrations studied (5-40 microM).

Furthermore, entacapone neither increased mitochondrial respiration nor 
impaired cardiac function at pharmacologically relevant concentrations (< 10 
microM).

In fact, the threshold concentration for increased mitochondrial oxygen 
consumption was 20 microM and half-maximal stimulation of respiration was not 
detected until 58 microM.

Surprisingly, tolcapone, another catechol-O-methyltransferase inhibitor, which 
acts both peripherally and centrally, stimulated respiration in L1210 cells at 
the lowest concentration studied (5 microM).

In addition, 1 microM tolcapone increased mitochondrial respiration, indicating 
that it caused uncoupling at a much lower concentration than that of 
2,4-dinitrophenol, a well-known uncoupler of oxidative phosphorylation.

Tolcapone also impaired the mechanical function and oxygen consumption of the 
isolated guinea-pig heart at 1 microM.

These results show that peripherally acting entacapone, unlike the 
brain-penetrating tolcapone, is a safe catechol-O-methyltransferase inhibitor 
for the treatment of Parkinson's disease, since it does not interfere with 
mitochondrial energy metabolism at pharmacologically effective concentrations.


Eur J Pharmacol 1997 Dec 11;340(2-3):287-94
Nissinen E, Kaheinen P, Penttila KE, Kaivola J, Linden IB
Orion Pharma Research, Espoo, Finland.
<erkki.nissinen@xxxxxxxxxxxxxxxx>
PMID: 9537825, UI: 98141050

<>

janet paterson
52 now / 41 dx / 37 onset
613 256 8340 po box 171 almonte ontario canada K0A 1A0
a new voice: <>
<janet313@xxxxxxxxxxx>


Parkinsn's List Subject Index

Parkinsn's List Thread Index

Parkinsn's Archive Treasures Doctors, students, patients and caregivers find current Parkinson's information such as the Algorithm, Caregivers Handbook, and talks by respected Movement Disorder Specialists.

Mail converted by MHonArc 2.6.10
Site Hosting donated by He.net
&
Grant from The Parkinson Alliance